DelMar Pharmaceuticals Delivers an Address and Presents an Overview of Upcoming GBM Trials with VAL-083 at the CNS Anticancer Drug Discovery Development Conference and Society for NeuroOncology Annual Meeting

November 21, 2016
DelMar Pharmaceuticals

Proposed Pivotal Phase III Clinical Trial in bevacizumab-failed glioblastoma multiforme (GBM) to enroll 180 patients with target completion in well under two years Two separate collaborator-supported Phase II studies designed to position VAL-083 as a new chemotherapeutic for the treatment of GBM Patients with unmethylated MGMT will be conducted in parallel with Phase III VANCOUVER, … Continue reading DelMar Pharmaceuticals Delivers an Address and Presents an Overview of Upcoming GBM Trials with VAL-083 at the CNS Anticancer Drug Discovery Development Conference and Society for NeuroOncology Annual Meeting

Mapping the human epigenome in pursuit of medical breakthroughs

November 17, 2016

Vancouver, BC — Much progress has been made since researchers mapped the human genome over a decade ago. The information has offered insights leading to innovation in health care including new ways to treat diseases, but there are still many unanswered questions in the fight against complex diseases like asthma, diabetes and cancer. Researchers believe … Continue reading Mapping the human epigenome in pursuit of medical breakthroughs

Arbutus Presents HBV Drug Combination Studies at AASLD

November 14, 2016

Combinations of Arbutus RNAi and Capsid Assets and Approved Drugs Show Complementary Action Capsid Inhibitor AB-423 Has Dual Mode of Action; Inhibits HBV DNA and cccDNA Synthesis Second Generation RNAi Agent ARB-1740 Improves Upon Potency of Lead RNAi Program VANCOUVER, B.C. and DOYLESTOWN, Pa., Nov. 14, 2016 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an … Continue reading Arbutus Presents HBV Drug Combination Studies at AASLD

bioLytical Launches World’s Fastest HIV Self Test in UK

LONDON, UK, [November 14, 2016 /CNW/] – Ahead of European HIV Testing Week (18-25 November), the world’s fastest HIV self-test will go on sale in the UK, relieving pressure on overcrowded sexual health clinics. bioLytical Laboratories, a world leader in rapid infectious disease tests, has developed the INSTI® HIV Self Test following research revealing that … Continue reading bioLytical Launches World’s Fastest HIV Self Test in UK

DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2017 Financial Results and Corporate Update

Company will host a business update conference call and webcast on Tuesday, November 15, 2016 at 4:30 PM EST The Company also highlights recent corporate and clinical achievements and provides an overview of expected near-term milestones. VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 14, 2016 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” and … Continue reading DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2017 Financial Results and Corporate Update

Aquinox Pharmaceuticals Announces Third Quarter 2016 Financial Results

November 9, 2016

VANCOUVER, British Columbia, Nov. 09, 2016 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today provided a corporate update and reported financial results for the third quarter ending September 30, 2016. “In September we commenced enrollment in the LEADERSHIP … Continue reading Aquinox Pharmaceuticals Announces Third Quarter 2016 Financial Results

Xenon Pharmaceuticals to Present at the Stifel 2016 Healthcare Conference

November 8, 2016

BURNABY, British Columbia, Nov. 08, 2016 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon’s President and Chief Executive Officer, will present a corporate update at the Stifel 2016 Healthcare Conference in New York, NY on Tuesday, November 15, 2016 at 3:00 pm ET. A live … Continue reading Xenon Pharmaceuticals to Present at the Stifel 2016 Healthcare Conference

DelMar Pharmaceuticals Presents New VAL-083 Data at Two International Scientific Conferences

November 7, 2016

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 7, 2016 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the Company and its research collaborators have presented data at two scientific conferences hosted by the American Association … Continue reading DelMar Pharmaceuticals Presents New VAL-083 Data at Two International Scientific Conferences

Arbutus Provides Corporate Update and Announces Third Quarter 2016 Financial Results

November 4, 2016

Additional ARB-1467 Multi-Dose Data in 4Q16Cash Runway into Late 2018 VANCOUVER, B.C. and DOYLESTOWN, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced its third quarter 2016 unaudited financial results and provided a corporate update. “This was an important quarter as we … Continue reading Arbutus Provides Corporate Update and Announces Third Quarter 2016 Financial Results

Xenon Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update

BURNABY, British Columbia, Nov. 03, 2016 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended September 30, 2016 and provided a corporate update. Dr. Simon Pimstone, Xenon’s President and Chief Executive Officer, said, “We have continued our momentum with a strong quarter, which included … Continue reading Xenon Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update